Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Survival analysis of the metastatic cohort of Italian Association of Medical Oncology (AIOM) GARIBALDI survey.
Reni M, Giommoni E, Bergamo F, Cavanna L, Simionato F, Spada M, Di Marco M, Bernardini I, Cordio SS, Latiano T, Spallanzani A, Silvestris N, Cardellino GG, Bonomi M, Milella M, Luchena G, Tamburini E, Macchini M, Orsi G, Modesti M, Procaccio L, Santoni A, De Simone I, Caldirola L, Galli F, Pinto C. Reni M, et al. Among authors: spallanzani a. Pancreatology. 2024 Nov;24(7):1160-1166. doi: 10.1016/j.pan.2024.10.002. Epub 2024 Oct 3. Pancreatology. 2024. PMID: 39389862 Free article.
Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study.
Di Bartolomeo M, Niger M, Tirino G, Petrillo A, Berenato R, Laterza MM, Pietrantonio F, Morano F, Antista M, Lonardi S, Fornaro L, Tamberi S, Giommoni E, Zaniboni A, Rimassa L, Tomasello G, Sava T, Spada M, Latiano T, Bittoni A, Bertolini A, Proserpio I, Bencardino KB, Graziano F, Beretta G, Galdy S, Ventriglia J, Scagnoli S, Spallanzani A, Longarini R, De Vita F. Di Bartolomeo M, et al. Among authors: spallanzani a. Target Oncol. 2018 Apr;13(2):227-234. doi: 10.1007/s11523-018-0562-5. Target Oncol. 2018. PMID: 29582224
Lenvatinib as a therapy for unresectable hepatocellular carcinoma.
Spallanzani A, Orsi G, Andrikou K, Gelsomino F, Rimini M, Riggi L, Cascinu S. Spallanzani A, et al. Expert Rev Anticancer Ther. 2018 Nov;18(11):1069-1076. doi: 10.1080/14737140.2018.1524297. Epub 2018 Sep 21. Expert Rev Anticancer Ther. 2018. PMID: 30220234 Review.
Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study.
Casadei-Gardini A, Scarpi E, Ulivi P, Palladino MA, Accettura C, Bernardini I, Spallanzani A, Gelsomino F, Corbelli J, Marisi G, Ruscelli S, Valgiusti M, Frassineti GL, Passardi A. Casadei-Gardini A, et al. Among authors: spallanzani a. Cancer Manag Res. 2019 May 10;11:4357-4369. doi: 10.2147/CMAR.S198651. eCollection 2019. Cancer Manag Res. 2019. PMID: 31191000 Free PMC article.
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer.
Salati M, Filippi R, Vivaldi C, Caputo F, Leone F, Salani F, Cerma K, Aglietta M, Fornaro L, Sperti E, Di Maio M, Ortega C, Fenocchio E, Lombardi P, Cagnazzo C, Depetris I, Gelsomino F, Spallanzani A, Santini D, Silvestris N, Aprile G, Roviello G, Scartozzi M, Cascinu S, Casadei-Gardini A. Salati M, et al. Among authors: spallanzani a. Liver Int. 2020 Mar;40(3):704-711. doi: 10.1111/liv.14314. Epub 2019 Dec 11. Liver Int. 2020. PMID: 31773848
Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis.
Casadei-Gardini A, Vagheggini A, Gelsomino F, Spallanzani A, Ulivi P, Orsi G, Rovesti G, Andrikou K, Tamburini E, Scartozzi M, Cascinu S. Casadei-Gardini A, et al. Among authors: spallanzani a. Clin Colorectal Cancer. 2020 Jun;19(2):82-90.e9. doi: 10.1016/j.clcc.2019.10.001. Epub 2020 Mar 17. Clin Colorectal Cancer. 2020. PMID: 32192883
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial.
Cascinu S, Berardi R, Bianco R, Bilancia D, Zaniboni A, Ferrari D, Mosconi S, Spallanzani A, Cavanna L, Leo S, Negri F, Beretta GD, Sobrero A, Banzi M, Morabito A, Bittoni A, Marciano R, Ferrara D, Noventa S, Piccirillo MC, Labianca R, Mosconi C, Casadei Gardini A, Gallo C, Perrone F. Cascinu S, et al. Among authors: spallanzani a. Eur J Cancer. 2021 May;148:422-429. doi: 10.1016/j.ejca.2021.02.023. Epub 2021 Mar 31. Eur J Cancer. 2021. PMID: 33812334 Clinical Trial.
TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study.
Raimondi A, Palermo F, Prisciandaro M, Aglietta M, Antonuzzo L, Aprile G, Berardi R, Cardellino GG, De Manzoni G, De Vita F, Di Maio M, Fornaro L, Frassineti GL, Granetto C, Iachetta F, Lonardi S, Murialdo R, Ongaro E, Pucci F, Ratti M, Silvestris N, Smiroldo V, Spallanzani A, Strippoli A, Tamberi S, Tamburini E, Zaniboni A, Di Bartolomeo M, Cremolini C, Sposito C, Mazzaferro V, Pietrantonio F. Raimondi A, et al. Among authors: spallanzani a. Cancers (Basel). 2021 Jun 7;13(11):2839. doi: 10.3390/cancers13112839. Cancers (Basel). 2021. PMID: 34200267 Free PMC article.
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey.
Orsi G, Di Marco M, Cavaliere A, Niger M, Bozzarelli S, Giordano G, Noventa S, Rapposelli IG, Garajova I, Tortora G, Rodriquenz MG, Bittoni A, Penzo E, De Lorenzo S, Peretti U, Paratore C, Bernardini I, Mosconi S, Spallanzani A, Macchini M, Tamburini E, Bencardino K, Giommoni E, Scartozzi M, Forti L, Valente MM, Militello AM, Cascinu S, Milella M, Reni M. Orsi G, et al. Among authors: spallanzani a. ESMO Open. 2021 Oct;6(5):100238. doi: 10.1016/j.esmoop.2021.100238. Epub 2021 Aug 13. ESMO Open. 2021. PMID: 34392104 Free PMC article.
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv).
Orsi G, Cavaliere A, Tortora G, Lonardi S, Macchini M, Di Marco M, Giordano G, Vasile E, Scartozzi M, Bozzarelli S, Noventa S, Rodriquenz MG, Militello AM, Rapposelli IG, Garajova I, De Lorenzo S, Merelli B, Bittoni A, Salvatore L, Procaccio L, Paratore C, Spallanzani A, Peretti U, Niger M, Giommoni E, Bernardini I, Tamburini E, Bernardino K, Forti L, Valente MM, Cascinu S, Milella M, Reni M. Orsi G, et al. Among authors: spallanzani a. Br J Cancer. 2023 Mar;128(5):877-885. doi: 10.1038/s41416-022-02086-w. Epub 2022 Dec 8. Br J Cancer. 2023. PMID: 36482190 Free PMC article.
98 results